Corporate Governance

Woman in Senior Management Positions

Specification to promote the participation of women in executive positions pursuant to Sections 76 Paragraph 4 and 111 Paragraph 5 of the German Stock Corporation Act (Aktiengesetz - AktG)
 

Promotion of women in executive positions

An adequate representation of women in the workforce and, in particular, among the executives, provides an important added value to the Biotest Group. The “German Act on the Equal Participation of Women and Men in Executive Positions in the Private Economy and the Public Service”, as amended and supplemented by the "Act to Supplement and Amend the Regulations for the Equal Participation of Women in Leadership Positions in the Private Sector and in the Public Sector" (so-called "Second Leadership Positions Act"),which came into force on August 12 2021, provides that companies such as Biotest AG, which are listed on the stock exchange and are subject to co-determination in accordance with the One-Third Participation Act (Drittelbeteiligungsgesetz), must set their own targets for gender participation. Second Leadership Positions Act), provides for companies such as Biotest AG, which are listed on the stock exchange and subject to co-determination in accordance with the One-Third Participation Act, to set themselves target figures for gender distribution on the Supervisory Board, Board of Management and subordinate management levels.
In accordance with this, Biotest AG set target figures for the participation of women in executive positions, which are to be met by 1 January 2024.

Women on the Supervisory Board

The Supervisory Board of Biotest AG is composed of six members, four of whom represent the shareholders, and two of whom represent the employees. The Supervisory Board is composed of one woman as representative of the shareholders, and one woman as a representative of the employees. By that proportion of 66.6 % of the seats on the Supervisory Board held by men and 33.3 % by women, the Company has exceeded the minimum target of 30 % women.

Women on the Board of Management

There were no women on the Board of Management in financial year 2021. This is in line with the set target of 0% for 2021. While the Supervisory Board does not consider a change in the composition of the Board of Management or an increase solely for the purpose of increasing the quota of women, the Supervisory Board decided that a successor of CEO, CFO or COO shall be female. For the decision to appoint Dr. Jörg Schüttrumpf as a further member of the Board of Management the professional qualifications were decisive. By 1 January 2024, the proportion of women on the Board of Management is to increase to 33%.

Women at the first and second management level

The Board of Management of Biotest AG has set a target figure of 20 % for the participation of women at the first management level by 30 June 2022 and has already exceeded this target by 31 December 2021 with 21,4 %. The target figure for the second management level was set at 30 % by 30 June 2022 and as of 31 December 2021, the proportion of women at that management level was 33,3 %. The proportion of women at Biotest AG (540 female employees) was 40,6 % as of 31 December 2021.